Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CELEXA vs TIGLUTIK KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.
Glutamate antagonist that inhibits presynaptic glutamate release via sodium channel blockade and modulation of excitatory amino acid transport.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
Amyotrophic lateral sclerosis (ALS)
20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.
50 mg orally every 12 hours, administered via enteral tube (e.g., nasogastric tube) as a suspension after mixing contents of the 5 mg/m L oral suspension packet with 10 m L of water.
Terminal elimination half-life is approximately 35 hours (range 23–45 h) in healthy adults. This long half-life allows once-daily dosing; steady state is reached in about 1 week. In elderly patients, half-life may extend to 45–90 hours.
Terminal elimination half-life is approximately 9-15 hours, with a mean of 12 hours. Steady-state is reached within 5-7 days. Clinically, this supports twice-daily dosing.
Hepatic via CYP2C19 (major), CYP3A4, and CYP2D6; active metabolites: S-demethylcitalopram and didemethylcitalopram.
Hepatic metabolism primarily via CYP1A2, with minor contributions from CYP3A4 and glucuronidation.
Primarily renal: 75% as metabolites (10% as parent citalopram, 65% as desmethylcitalopram, didesmethylcitalopram, and citalopram-N-oxide). Fecal excretion accounts for approximately 20% of the dose. Biliary excretion minimal.
Riluzole is primarily eliminated via hepatic metabolism, with <10% excreted unchanged in urine. Metabolites are eliminated renally (~85%) and fecally (~5%).
Approximately 80% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Binding is independent of drug concentration.
97% bound primarily to plasma proteins, including albumin and lipoproteins.
Mean Vd is 12 L/kg (range 8–16 L/kg). This large Vd indicates extensive extravascular distribution, including CNS penetration. High Vd contributes to the long half-life.
Approximately 3.4 L/kg, indicating extensive tissue distribution, particularly into the CNS.
Oral bioavailability is approximately 80% (range 60–90%). No significant first-pass metabolism. Food does not affect bioavailability.
Oral bioavailability is approximately 60% (range 36-76%) due to extensive first-pass metabolism. High-fat meals reduce AUC by 20% and Cmax by 45%.
GFR >20 m L/min: no adjustment; GFR ≤20 m L/min: maximum 20 mg/day; not recommended for GFR <10 m L/min.
No dose adjustment required for mild to moderate renal impairment (Cr Cl 30-89 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
Child-Pugh Class A: 10 mg once daily; Child-Pugh Class B or C: maximum 20 mg/day with careful titration.
Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B), but use with caution.
Adolescents 12-17 years: 10 mg orally once daily initially, may increase to 20 mg once daily after 3 weeks; maximum 20 mg/day. Children <12 years: not approved.
Not approved for pediatric patients under 18 years of age. Safety and efficacy have not been established.
Patients >60 years: 10 mg orally once daily initially, maximum 20 mg once daily.
No specific dose adjustment recommended based on age alone; consider renal function and overall frailty. Monitor for adverse effects, particularly falls and dysphagia.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
None
QT prolongation, serotonin syndrome, hyponatremia, increased risk of bleeding, activation of mania/hypomania, seizures, angle-closure glaucoma, sexual dysfunction, and discontinuation syndrome.
Hepatic injury (elevated transaminases, bilirubin),Neutropenia,Interstitial lung disease,Dizziness and somnolence
Concomitant use with MAOIs or within 14 days of MAOI use, concomitant use with pimozide, hypersensitivity to citalopram or any excipients.
Hypersensitivity to riluzole or any component of the formulation,Concomitant use with tizanidine,Severe hepatic impairment (Child-Pugh class C)
No specific food interactions. Avoid grapefruit and grapefruit juice as they may increase citalopram levels via CYP3A4 inhibition. Alcohol may exacerbate CNS depression and should be avoided.
Avoid high-fat meals (e.g., fried foods, cheese, creamy sauces) within 1 hour before or 2 hours after dosing, as they increase absorption and may increase risk of side effects. Grapefruit juice may increase riluzole levels; avoid concurrent consumption.
First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third trimester: Risk of persistent pulmonary hypertension of the newborn (PPHN), preterm birth, low birth weight; late third trimester exposure may cause neonatal adaptation syndrome (irritability, respiratory distress, feeding difficulties).
FDA Pregnancy Category C. Animal studies show fetal harm at 0.6 times human dose; no adequate human studies. First trimester: potential organogenesis disruption; use only if benefit justifies risk. Second/third trimesters: possible fetal growth restriction; avoid if possible.
Citalopram is excreted into breast milk; average infant dose relative to maternal weight-adjusted dose is 3.9% (range 1.7-8.5%). Milk-to-plasma ratio (M/P) approximately 1.5. Cases of adverse effects in breastfed infants (excessive somnolence, poor feeding) reported; caution with higher maternal doses. Benefits of breastfeeding generally outweigh risks for mild cases, but alternative agents with lower M/P (e.g., sertraline, paroxetine) may be preferred for moderate-severe depression.
Excretion into human milk unknown; M/P ratio not established. Caution advised; consider discontinuing nursing or drug based on importance to mother.
Pregnancy may reduce citalopram plasma concentrations by 30-50% due to increased volume of distribution and enhanced hepatic clearance (CYP2C19 induction). Dose adjustment should be guided by clinical response (depressive symptom monitoring) and trough serum concentrations if available. A 30-50% dose increase (e.g., from 20 mg to 30-40 mg) may be needed, especially in third trimester. Postpartum: Dose should be tapered back to pre-pregnancy levels within 1–2 weeks to avoid toxicity.
No standard dose adjustments established; pharmacokinetics in pregnancy not studied; monitor clinical response and adjust based on tolerability.
Celexa (citalopram) is an SSRI antidepressant. Key pearls: (1) Max dose 40 mg/day due to QT prolongation risk at higher doses; (2) CYP2C19 and CYP3A4 metabolism; avoid with MAOIs and linezolid; (3) Onset of therapeutic effect takes 2-4 weeks; (4) More selective for serotonin reuptake than fluoxetine or paroxetine, with fewer drug interactions; (5) May cause mild SIADH in elderly; (6) Abrupt discontinuation can cause withdrawal syndrome; (7) Electrolyte monitoring recommended in patients at risk for QT prolongation.
Tiglutik (riluzole) is the first liquid formulation of riluzole, approved for ALS. It can be administered via feeding tube. Monitor liver function tests (ALT, AST) monthly for 3 months, then quarterly. Avoid use in patients with baseline transaminase elevations >3x ULN. Concomitant use with hepatotoxic drugs (e.g., NSAIDs, acetaminophen >3 g/day) requires caution. Has a high fat emulsion suspension; do not dilute.
Take exactly as prescribed; do not increase dose without consulting your doctor.,It may take 2-4 weeks to feel the full benefit; do not stop abruptly.,Avoid alcohol while taking this medication.,Report any symptoms of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, muscle stiffness) immediately.,Notify your doctor if you experience unusual bleeding or bruising, or if you have a history of QT prolongation or electrolyte disturbances.
Take each dose at least 1 hour before or 2 hours after a meal to avoid food interactions.,Shake the bottle well for at least 30 seconds before each use.,Use the provided dosing syringe to measure the correct dose; do not use household spoons.,If you miss a dose, take it as soon as you remember unless it is close to the next dose; do not double-dose.,Report any yellowing of skin or eyes, dark urine, or abdominal pain immediately as signs of liver toxicity.,You may feel dizzy or lightheaded; avoid driving until you know how the drug affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CELEXA vs TIGLUTIK KIT, answered by our medical review team.
CELEXA is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.. TIGLUTIK KIT is a Amyotrophic Lateral Sclerosis Agent that works by Glutamate antagonist that inhibits presynaptic glutamate release via sodium channel blockade and modulation of excitatory amino acid transport.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CELEXA and TIGLUTIK KIT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CELEXA is: 20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.. The standard adult dose of TIGLUTIK KIT is: 50 mg orally every 12 hours, administered via enteral tube (e.g., nasogastric tube) as a suspension after mixing contents of the 5 mg/m L oral suspension packet with 10 m L of water.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CELEXA and TIGLUTIK KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CELEXA is classified as Category C. First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third. TIGLUTIK KIT is classified as Category C. FDA Pregnancy Category C. Animal studies show fetal harm at 0.6 times human dose; no adequate human studies. First trimester: potential organogenesis disruption; use only if benefi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.